- The goal of diagnostic testing for Ebola and Marburg virus diseases is to identify cases to provide timely and appropriate care and to stop disease transmission.
- All individuals meeting the case definition for Ebola or Marburg virus diseases should be tested.
- The recommended sample type ...for testing for orthoebolaviruses and orthomarburgviruses is whole blood or plasma for living patients, and oral swab for deceased individuals.
- Laboratory confirmation of Orthoebolavirus and Orthomarburgvirus infections and further species identification should be done using nucleic acid amplification testing (NAAT).
- If a suspected case tests negative (living patient) and the blood was drawn less than 72 hours after symptom onset, a second test should be performed with blood drawn more than 72 hours after symptom onset.
- All manipulations in laboratory settings of samples originating from suspected, probable or confirmed cases of Ebola and Marburg virus diseases should be conducted with appropriate biosafety measures according to a risk-based approach.
- Whole or partial genome sequencing can be used to characterize viruses and complement epidemiologic investigations.
- Member States are strongly encouraged to share genetic sequence data (GSD) in publicly accessible databases.
- Member States are required to immediately notify the World Health Organization (WHO) under the International Health Regulations (IHR) 2005 of positive laboratory results.
more
Disaster Preparedness Training Programme
20 February 2013
Update on 2004 Background Paper (Written by Saloni Tanna)
Priority Medicines for Europe and the World "A Public Health Approach to Innovation"
Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection
Accessed: 26.02.2020
This report, examining the mood of a country that holds the top spot in the Fragile States Index, is based on field research conducted in South Sudan in April and May 2014.
Asylum and Migration Working Paper 1
These guidelines for the National Pharmacovigilance and Medicine Information System in Rwanda have been developed to ensure that safe, efficacious and quality medicines are made available to all Rwandans.
UNAIDS 2016 / Meeting Report
Emergencias 2021: 33: 42-58
PLOS Glob Public Health 4(12): e0004035. https://doi. org/10.1371/journal.pgph.0004035.
A new formulation of praziquantel, arpraziquantel (arPZQ), has been developed for preschool-
aged children (PSAC) to fill the treatment gap for this age group in schistosomiasis control and
elimination program...s. There is now a priority to ensure that the drug reaches all at-risk PSAC
in endemic areas, including hard-to-reach areas and populations. This study aimed to deter-
mine schistosomiasis treatment-related contextual factors among fishermen and island popu-
lations in Homa Bay County, Kenya, and to identify a suitable platform to deliver arPZQ.
more
Journal of Social Aspects of HIV/AIDS VOL. 13 NO. 1 2016
To link to this article: https://doi.org/10.1080/17290376.2016.1226942
BJPSYCH INTERNATIONALVOLUME 12NUMBER 4NOVEMBER 2015